Abstract:Chronic liver injury is accompanied by a dysbalanced scarring process, termed fibrosis. This process is mainly driven by chronic inflammation and an altered activity of a multitude of different chemokines and cytokines, resulting in the infiltration by immune cells (especially macrophages) and increase of matrix-expressing cell types. These processes might lead to cirrhosis representing the end-stage of fibrosis. Recent clinical studies comprising patients successfully treated for viral hepatitis showed that liver fibrogenesis and even cirrhosis may be reverted. The hepatic capacity to remodel scar tissue and to revert into a normal liver follows specific mechanistic principles that include the termination of chronic tissue damage, shifting the cellular bias from inflammation to resolution, initiation of myofibroblast apoptosis or senescence and, finally, fibrinolysis of excess scar tissue. The plurality of molecular and cellular triggers involved in initiation, progression and resolution of hepatic fibrogenesis offers an infinite number of therapeutic possibilities. For instance, inflammatory macrophages can be targeted via inhibition of chemokine CCL2 or its receptor CCR2 (e.g., by cenicriviroc) as well as by transfer of restorative macrophage subsets. Another target is galectin-3 that acts at various stages along the continuum from acute to chronic inflammation. Profibrogenic cytokines (e.g., transforming growth factor-β), matricellular proteins (e.g., CCN1/CYR61) or signaling pathways involved in fibrogenesis offer further possible targets. Other options are the application of therapeutic antibodies directed against components involved in biogenesis or remodeling of connective tissue such as lysyl oxidase-like-2 or synthetic bile acids like obeticholic acid that activate the farnesoid X receptor and was antifibrotic in a phase 2 study (FLINT trial). Factors affecting the gut barrier function or the intestinal microbiome further expanded the repertoire of drug targets. In this review, we discuss novel concepts in resolution of hepatic fibrosis and focus on drug targets that might be suitable to trigger resolution of fibrosis.

Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit

1105 Effects and mechanisms of tranilast in inhibiting keloid fibrosis

Therapeutic Targeting of Src Kinase and Myofibroblast Activation in Pulmonary Fibrosis

Hitting the Target! Challenges and Opportunities for TGF-β Inhibition for the Treatment of Cardiac fibrosis

Clinical Advancements in the Targeted Therapies against Liver Fibrosis

Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues

Tranilast inhibits angiotensin II-induced myocardial fibrosis through S100A11/ transforming growth factor-β (TGF-β1)/Smad axis

Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis

Potential of Plant-Derived Compounds in Preventing and Reversing Organ Fibrosis and the Underlying Mechanisms

Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Liver Fibrosis: From Pathogenesis to Novel Therapies

Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis

Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis

Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis

Targeted liposomes for macrophages-mediated pulmonary fibrosis therapy

Therapeutic targets of fibrosis: Translational advances and current challenges

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

Emerging delivery approaches for targeted pulmonary fibrosis treatment